Home / Health / Study shows that remdesivir reduces ICU time for patients with COVID-19 – Health

Study shows that remdesivir reduces ICU time for patients with COVID-19 – Health



The United States purchased almost all of its drug production over the next three months, after positive results (photo: ULRICH PERREY / AFP - 8/4/20)
The United States purchased almost all production of the drug in the next three months, after positive results (photo: ULRICH PERREY / AFP – 8/4/20)

Considered one of the most promising test drugs against new coronavirus, remdesivir can save lives in countries with less hospital capacity to deal with the pandemic. The conclusion is a study by the School of Public Health of Boston University, in the United States, signaling a way out for governments beginning to suffer from the overload of intensive care unit requirements (ICUs), such as Africans and Latinos. New studies show that antivirally developed to treat ebola reduces the average stay time in the ICU from 15 to 11 days and with 30% deaths due to COVID-19.

The study authors analyzed this information and the epidemiological reality in South Africa, which has the largest number of cases on the continent, and concluded that the use of remdesivir can increase the number of patients treated in the ICU by more than 50%. Thus, up to 6,682 lives per month would be saved.

Projections also showed that if direct treatment with remdesivir it also saves lives for more than 30% of patients – the current estimate of the drug – the dual effect of the antiviral can prevent up to 13,647 deaths in South Africa in December.

According to WORLD HEALTH ORGANIZATION (WHO) counts the country 205,721 infected and 3,300 dead and has had a significant increase in cases since last month.

For example, on June 4, 1,713 cases were registered. On July 4, 9,063.

Although the analysis is limited to the South African reality, the North American team believes that the strategy can increase the turnover of intensive care units elsewhere. “There are many countries with limited ICU capacity that can benefit from this dual impact on mortality,” said Brooke Nichols, lead author of the study, peer-reviewed and published in the journal, in a statement. Clinical infectious diseases.

Brooke Nichols, who is also assistant professor of global health at the university, says he is worried about the news that the United States has bought much of that cure.

According to him, there is a risk of misallocation of resources if the government is not sure that the priority of using the antiviral will be given to congested places in the country.

“Why would you use a drug with limited availability to save a life when the same drug could be used to save two?”

Remdesivir is one of the drugs that is still on the list of potential measures against COVID-19. Hydroxychloroquine, defended by President Jair Bolsonaro, is no longer being tested by WHO.

Different realities

Nichols and co-authors of the study have modeled the epidemic of covid-19 in South Africa to assist the country’s government in decision-making.

By analyzing the epidemiology model for the disease, they concluded that if each of the patients with the disease treated in the ICUs received remission, the number of people treated would increase from 23,443 to 32,284 in June to 36,383 to 47,820 in December.

However, the team emphasizes that in order to reach these figures, it is necessary for the therapy units to function properly: effect on intensive care has been structured ”.

The team also considers that mortality in ICUs is changing from country to country and from hospital to hospital. Thus, the prognosis for the number of lives saved due to intensive care capacity also varies.

Another point to consider is the importance of new studies that reveal the impact of other treatment options, such as the use of dexamethasone, on the length of ICU patients and the risk of death.

Among the countries that use the antiviral to fight COVID-19 are South Korea and India.

Almost exclusive stock in the USA

Earlier this month, the US Department of Health and Social Services (HHS) announced that it had concluded an agreement with the California Laboratory Gilead Sciences to buy virtually all the global share from remdesivir.

100% of the antiviral production in July will be in the country, 90% in August and 90% in September.

“We want to make sure that all American patients who need help can get it,” the Secretary of Health and Human Services US, Alex Azar.

Remdesivir-based treatment uses six doses and costs an average of $ 3,200. President’s announcement Donald Trump The massive acquisition of the drug and Gilead at the price of the treatment has drawn criticism around the world.

What is coronavirus

Coronavirus is a large family of viruses that cause respiratory tract infections. The new coronavirus (COVID-19) was discovered in December 2019 in China. The disease can cause infections with symptoms that are initially similar to colds or mild flu, but with the risk of getting worse, which can lead to death.
Video: Why not spread everything you get on Whatsapp

How is COVID-19 transmitted?

Coronavirus transmission is usually carried out by air or by personal contact with contaminated secretions, such as saliva drops, sneezing, cough, mucus, near personal contact, such as touch or handshake, contact with contaminated objects or surfaces, followed by contact with mouth, nose or eyes. .

Video: People without symptoms transmit the corona virus?

How to prevent it?

The recommendation is to avoid congestion, stay away from those who exhibit symptoms of respiratory infection, wash their hands frequently, cough with the forearm in front of the mouth and use soap and water to wash their hands or alcohol gel after contact with surfaces and people. At home, be extra careful about COVID-19.
Video: The flexibility of insulation “is not generally released”; know why

What are the symptoms of coronavirus?

Check out the most important symptoms of people infected with COVID-19:

  • Fever
  • Cough
  • Shortness of breath and difficulty breathing
  • Stomach Problems
  • Diarrhea

In severe cases, the victims have:

  • Pneumonia
  • Severe acute respiratory illness
  • Renal impairment

The type of COVID-19 symptoms increase every week as researchers continue to identify the virus’s behavior.

Video explains why you should “learn to cough”


Myths and truths about the virus

On social media, COVID-19 also spread rumors about how SARS-CoV-2 virus transmitted. And other questions arose: Can alcohol gel kill the virus? Is coronavirus deadly on a worrying level? Can an infected person infect several others? Will the epidemic kill thousands of Brazilians, since SUS could not serve everyone? We did a report with a doctor for infectious diseases and he explains all the myths and truths about the coronavirus.

Coronavirus and outdoor activities: video shows what science says

To learn more about coronavirus, also read:


Source link